Dashboard
Manage Tickers

KYMRKymera Therapeutics, Inc.

Nasdaq kymeratx.com


$ 32.11 $ -0.09 (-0.28 %)    

Friday, 31-May-2024 15:55:24 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 454.82 $ -0.45 (-0.1 %)
DIA $ 398.57 $ 4.73 (1.24 %)
SPY $ 530.36 $ 1.87 (0.36 %)
TLT $ 91.26 $ -0.02 (-0.02 %)
GLD $ 225.37 $ -1.97 (-0.91 %)
$ 32.16
$ 32.20
$ 32.11 x 200
$ 0.00 x 0
$ 31.51 - $ 33.01
$ 9.60 - $ 45.31
604,436
na
2.28B
$ 2.15
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-02-2024 03-31-2024 10-Q
2 02-22-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 02-23-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-03-2022 03-31-2022 10-Q
10 02-24-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-06-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 03-11-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

demystifying-kymera-therapeutics-insights-from-5-analyst-reviews
Demystifying Kymera Therapeutics: Insights...
05/24/2024 12:01:29

hc-wainwright--co-reiterates-buy-on-kymera-therapeutics-maintains-46-price-target
HC Wainwright & Co. Reiterates Buy on Kyme...
05/24/2024 11:04:35

HC Wainwright & Co. analyst Andrew Fein reiterates Kymera Therapeutics (NASDAQ:KYMR) with a Buy and maintains $46 price ...

kymera-therapeutics-plans-to-present-new-clinical-data-from-ongoing-phase-1-trial-of-mdm2-degrader-kt-253-at-asco-meeting
Kymera Therapeutics Plans To Present New C...
05/23/2024 21:24:54

 Jared Gollob, MD, Chief Medical Officer, Kymera Therapeutics, said "We look forward to sharing the full Phase 1 data set, ...

kymera-therapeutics-to-present-new-preclinical-data-for-kt-621-an-oral-stat6-degrader-at-the-ats-annual-meeting-kt-621-expected-to-start-phase-1-in-the-second-half-of-2024-with-phase-1-data-in-the-first-half-of-2025
Kymera Therapeutics To Present New Preclin...
05/22/2024 15:27:15

KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in preclinical stud...

kymera-therapeutics-presents-clinical-data-from-the-ongoing-phase-1-trial-of-stat3-degrader-kt-333-at-eha-annual-meeting-june-13-16-2024-in-madrid-spain
Kymera Therapeutics Present's Clinical Dat...
05/14/2024 14:03:24

Abstract released today highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-of...

oppenheimer-maintains-outperform-on-kymera-therapeutics-lowers-price-target-to-52
Oppenheimer Maintains Outperform on Kymera...
05/03/2024 13:09:26

Oppenheimer analyst Jeff Jones maintains Kymera Therapeutics (NASDAQ:KYMR) with a Outperform and lowers the price target fro...

kymera-therapeutics-q1-eps-069-beats-073-estimate-sales-1029m-miss-1369m-estimate
Kymera Therapeutics Q1 EPS $(0.69) Beats $...
05/02/2024 11:08:22

Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $...

kymera-therapeutics-stock-a-deep-dive-into-analyst-perspectives-5-ratings
Kymera Therapeutics Stock: A Deep Dive Int...
04/22/2024 13:00:52

oppenheimer-initiates-coverage-on-kymera-therapeutics-with-outperform-rating-announces-price-target-of-53
Oppenheimer Initiates Coverage On Kymera T...
04/22/2024 11:28:40

Oppenheimer analyst Jeff Jones initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Outperform rating and announce...

kymera-therapeutics-reveals-preclinical-data-on-cancer-fighting-drug-kt-333-at-aacr-meeting
Kymera Therapeutics Reveals Preclinical Da...
04/08/2024 11:05:26

 Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule me...

truist-securities-maintains-buy-on-kymera-therapeutics-raises-price-target-to-54
Truist Securities Maintains Buy on Kymera ...
03/01/2024 13:33:52

Truist Securities analyst Srikripa Devarakonda maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price t...

piper-sandler-maintains-overweight-rating-for-kymera-therapeutics-heres-what-you-need-to-know
Piper Sandler Maintains Overweight Rating ...
02/27/2024 17:00:35

piper-sandler-maintains-overweight-on-kymera-therapeutics-raises-price-target-to-56
Piper Sandler Maintains Overweight on Kyme...
02/27/2024 15:27:51

Piper Sandler analyst Edward Tenthoff maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price tar...

breaking-down-kymera-therapeutics-4-analysts-share-their-views
Breaking Down Kymera Therapeutics: 4 Analy...
02/23/2024 20:00:59

kymera-therapeutics-is-well-capitalized-with-745m-in-cash-and-runway-into-the-first-half-of-2027
Kymera Therapeutics Is Well-Capitalized Wi...
02/22/2024 12:04:33

kymera-therapeutics-q4-eps-025-beats-040-estimate-sales-4788m-beat-4196m-estimate
Kymera Therapeutics Q4 EPS $(0.25) Beats $...
02/22/2024 12:03:22

Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $...

earnings-scheduled-for-february-22-2024
Earnings Scheduled For February 22, 2024
02/22/2024 10:27:06

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on reve...

wolfe-research-initiates-coverage-on-kymera-therapeutics-with-peer-perform-rating
Wolfe Research Initiates Coverage On Kymer...
02/15/2024 11:45:05

Wolfe Research analyst Andy Chen initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Peer Perform rating.

kymera-therapeutics-outlines-key-2024-objectives-and-strategy-to-progress-leading-portfolio-of-immunology-and-oncology-programs-co-well-capitalized-with-cash-in-excess-of-745m-and-expected-runway-into-the-first-half-of-2027
Kymera Therapeutics Outlines Key 2024 Obje...
01/09/2024 14:19:25

IRAK4 oral degrader KT-474 (SAR444656) expected to complete enrollment in both Phase 2 HS and AD studies in fourth quarter of 2...

kymera-therapeutics-priced-275m-public-offering-at-2525share
Kymera Therapeutics Priced $275M Public Of...
01/05/2024 11:04:35

Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule med...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION